The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01279252
Recruitment Status : Unknown
Verified September 2015 by King's College Hospital NHS Trust. Recruitment status was: Active, not recruiting
The purpose of this study is to evaluate whether patients with previously untreated, early stage CLL respond to empirical broad spectrum antibiotics and therefore test the hypothesis that occult bacterial infections are involved in the induction and maintenance of CLL.
Condition or disease
Chronic Lymphocytic Leukaemia (CLL)
Drug: metronidazole, clarithromycin, ciprofloxacin and lansoprazole
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age > 18
ECOG performance status of 2 or less.
CLL with a diagnostic score of 4 or 5.
Clinical stage A disease.
No disease progression over a minimum of 1 month prior to commencement of therapy.
Less than 2 adverse prognostic factors.
Absence of adverse cytogenetics.
Expected survival > 6 months.
Able to give informed consent.
No clinical evidence of active infection at the time of study entry.
No known allergy to any of the study medications.
Renal and liver function tests within normal limits.
Disease progression during screening period.
Known positivity for HIV types 1 or 2.
Active infection at the time of screening.
Pregnancy or lactation.
Females of childbearing potential† and males not willing to practice an effective method of contraception whilst receiving the antibiotic regimen and for 4 weeks after the last dose.
Concomitant medication likely to produce serious interaction with study drugs including warfarin type oral anticoagulants and anti-epileptics.